The unique mechanism of action of RAB9 makes it an attractive, novel agent that may be combined with other chemotherapy agents and/or incorporated into CHOP‐based protocols in attempt to extend the time to lymphoma relapse and prolong ultimate drug resistance. This evidence concerns the gene RAB9A and lymphoma.